Kinda Recap of ASM
Sorry been extremely busy with work and family here are a few of the highlights:
1. Number #1 objection to adding Andexxa: Price. Thank you SG for the honesty.
2. Data on Kcentra vs Andexxa could be released in some form as soon as 6/21 with full study (this is an in house study) information released in Melbourne first week of July.
3. Pleased with the progress of Andexxa and expects continued straight line growth.
4. Would not provide information on possible partnerships or even if there were viable negotiations in progress for Andexxa in Europe and Betrixaban WW.
5. Scott Garland is 100x better than Lis in professionalism and truly presents as a solid leader.
Overall the mood is positive but with a clear realization the performance of the stock is more than a little disappointing.
I will add a bit more when I have a minute.